文献速递免疫规划卫生政策与健康促进

铝佐剂和CpG 1018佐剂的SARS-CoV-2重组蛋白亚单位疫苗(IndoVac)在印度尼西亚成年人中的免疫原性和安全性:一项3期、随机、阳性对照、多中心试验

Immunogenicity and safety of SARS-CoV-2 recombinant protein subunit vaccine (IndoVac) adjuvanted with alum and CpG 1018 in Indonesian adults: A phase 3, randomized, active-controlled, multicenter trial.
PubMed 文献 · Vaccine · 2024-04-04

Bio Farma公司研发的IndoVac重组蛋白亚单位疫苗在印度尼西亚18岁及以上未接种过SARS-CoV-2疫苗的成年人中开展3期随机阳性对照多中心试验,共纳入4050名参与者,比较IndoVac与Covovax的免疫原性和安全性。结果显示,第二剂后14天中和抗体几何平均比值(GMR)为1.01(95%CI 0.89-1.16),达到WHO免疫桥接非劣效标准;抗体水平维持至第二剂后12个月;不良事件发生率IndoVac组为27.95%,Covovax组为32.15%,多为轻度。结论认为IndoVac安全性良好且免疫应答非劣效于Covovax。

要点

  • 第二剂后14天中和抗体GMR为1.01(95%CI 0.89-1.16),达到WHO非劣效标准。
  • 抗体水平维持至第二剂后12个月。
  • 不良事件发生率IndoVac组27.95%、Covovax组32.15%,多为轻度(27.70%)。

核心结论

  • IndoVac在成年人中显示出良好的安全性特征,并诱导了非劣效于Covovax的免疫应答。

研究设计与样本

  • 随机、阳性对照、多中心、前瞻性干预研究,纳入印度尼西亚18岁及以上未接种过SARS-CoV-2疫苗的成年人,共4050名参与者于2022年6月至8月入组并至少接种一剂疫苗,受试者接种两剂IndoVac或对照疫苗Covovax(间隔28天),随访至全程接种后12个月。

主要发现

  • 第二剂后14天中和抗体几何平均比值(GMR)为1.01(95%CI 0.89-1.16),达到WHO免疫桥接非劣效标准(95%CI下限>0.67)。
  • 抗体水平维持至第二剂后12个月。
  • 不良事件发生率IndoVac组为27.95%,Covovax组为32.15%,大多为轻度(27.70%)。
  • 最常见的征集性不良事件为疼痛(14.69%),其次为肌痛(7.48%)和疲劳(6.77%)。
  • 非征集性不良事件各异,各发生率均低于5%;未发生被评估为与疫苗可能、很可能或肯定相关的严重不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bio Farma has developed a recombinant protein subunit vaccine (IndoVac) that is indicated for active immunization in population of all ages. This article reported the results of the phase 3 immunogenicity and safety study in Indonesian adults aged 18 years and above. METHODS: We conducted a randomized, active-controlled, multicenter, prospective intervention study to evaluate the immunogenicity and safety of IndoVac in adults aged 18 years and above. Participants who were SARS-CoV-2 vaccine-naïve received two doses of either IndoVac or control (Covovax) with 28 days interval between doses and were followed up until 12 months after complete vaccination. RESULTS: A total of 4050 participants were enrolled from June to August 2022 and received at least one dose of vaccine. The geometric mean ratio (GMR) of neutralizing antibody at 14 days after the second dose was 1.01 (95 % confidence interval (CI) 0.89-1.16), which met the WHO non-inferiority criteria for immunobridging (95 % CI lower bound > 0.67). The antibody levels were maintained through 12 months after the second dose. The incidence rate of adverse events (AEs) were 27.95 % in IndoVac group and 32.15 % in Covovax group with mostly mild intensity (27.70 %). The most reported solicited AEs were pain (14.69 %) followed by myalgia (7.48 %) and fatigue (6.77 %). Unsolicited AEs varied, with each of the incidence rate under 5 %. There were no serious AEs assessed as possibly, probably, or likely related to vaccine. CONCLUSIONS: IndoVac in adults showed favourable safety profile and elicited non-inferior immune response to Covovax. (ClinicalTrials.gov: NCT05433285, Indonesian Clinical Research Registry: INA-R5752S9).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Nurdin A, Movieta Nency Y, Maddeppungeng M, et al. Immunogenicity and safety of SARS-CoV-2 recombinant protein subunit vaccine (IndoVac) adjuvanted with alum and CpG 1018 in Indonesian adults: A phase 3, randomized, active-controlled, multicenter trial. Vaccine. 2024. PMID: 38575433. doi:10.1016/j.vaccine.2024.03.077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。